Prelude Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.67M | Buy |
154,970
+53,500
| +53% | +$1.72M | 0.36% | 57 |
|
|
2025
Q4 | $3.17M | Sell |
101,470
-51,918
| -34% | -$1.28M | 0.23% | 87 |
|
|
2025
Q3 | $3.1M | Sell |
153,388
-157
| -0.1% | -$2.76K | 0.24% | 86 |
|
|
2025
Q2 | $2.57M | Buy |
153,545
+109,465
| +248% | +$1.77M | 0.25% | 91 |
|
|
2025
Q1 | $678K | Buy |
44,080
+23,400
| +113% | +$418K | 0.05% | 420 |
|
|
2024
Q4 | $456K | Buy |
20,680
+4,055
| +24% | +$73.8K | 0.03% | 625 |
|
|
2024
Q3 | $300K | Buy |
16,625
+203
| +1% | +$3.55K | 0.02% | 866 |
|
|
2024
Q2 | $267K | Buy |
16,422
+94
| +0.6% | +$1.45K | 0.02% | 840 |
|
|
2024
Q1 | $230K | Buy |
+16,328
| New | +$206K | 0.01% | 1041 |
|
|
2020
Q4 | – | Sell |
-1,844
| Closed | -$17K | – | 1977 |
|
|
2020
Q3 | $17K | Buy |
+1,844
| New | +$19.5K | ﹤0.01% | 1363 |
|
|
2020
Q1 | – | Sell |
-12,912
| Closed | -$132K | – | 2015 |
|
|
2019
Q4 | $127K | Buy |
+12,912
| New | +$115K | ﹤0.01% | 1010 |
|
|
2019
Q3 | – | Sell |
-364
| Closed | -$2.79K | – | 2041 |
|
|
2019
Q2 | $3K | Sell |
364
-16,486
| -98% | -$199K | ﹤0.01% | 1556 |
|
|
2019
Q1 | $264K | Buy |
16,850
+3,249
| +24% | +$57.3K | 0.01% | 632 |
|
|
2018
Q4 | $210K | Buy |
13,601
+2,504
| +23% | +$51.3K | 0.01% | 708 |
|
|
2018
Q3 | $239K | Buy |
11,097
+9,603
| +643% | +$223K | 0.01% | 721 |
|
|
2018
Q2 | $36K | Buy |
+1,494
| New | +$30.5K | ﹤0.01% | 1212 |
|
|
2018
Q1 | – | Sell |
-36,188
| Closed | -$686K | – | 1718 |
|
|
2017
Q4 | $686K | Buy |
36,188
+18,529
| +105% | +$279K | 0.06% | 337 |
|
|
2017
Q3 | $311K | Buy |
+17,659
| New | +$397K | 0.03% | 509 |
|
|
2017
Q1 | – | Sell |
-18,500
| Closed | -$671K | – | 1765 |
|
|
2016
Q4 | $671K | Buy |
+18,500
| New | +$739K | 0.08% | 266 |
|
|
2016
Q3 | – | Sell |
-10,069
| Closed | -$506K | – | 1814 |
|
|
2016
Q2 | $506K | Buy |
10,069
+1,200
| +14% | +$63.9K | 0.07% | 284 |
|
|
2016
Q1 | $475K | Hold |
8,869
| – | – | 0.07% | 316 |
|
|
2015
Q4 | $582K | Sell |
8,869
-1,155
| -12% | -$71.4K | 0.09% | 244 |
|
|
2015
Q3 | $566K | Buy |
+10,024
| New | +$650K | 0.08% | 257 |
|
|
2015
Q1 | – | Sell |
-1,420
| Closed | -$82K | – | 2172 |
|
|
2014
Q4 | $82K | Sell |
1,420
-60
| -4% | -$3.34K | 0.01% | 1078 |
|
|
2014
Q3 | $80K | Sell |
1,480
-100
| -6% | -$5.3K | 0.01% | 1190 |
|
|
2014
Q2 | $83K | Buy |
+1,580
| New | +$80.8K | 0.01% | 1176 |
|
Other funds holding TEVA
HIIFS
PF
MMH
CI
MIFH
LIM
Prelude Capital Management's TEVA Position: Q1 2026 in Review
Prelude Capital Management increased its Teva Pharmaceuticals (TEVA) stake by 53% in Q1 2026, buying an estimated $1.72M and bringing the position to 154,970 shares worth $4.67M. The position accounts for 0.36% of the portfolio, ranked #57.
Prelude Capital Management first reported a position in TEVA in Q2 2014 and has held it in 26 quarters since. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.
- Prelude Capital Management held 154,970 shares of Teva Pharmaceuticals worth $4.67M as of Q1 2026.
- Prelude Capital Management bought 53,500 Teva Pharmaceuticals shares in Q1 2026, an estimated $1.72M.
- Teva Pharmaceuticals made up 0.36% of Prelude Capital Management's portfolio in Q1 2026, its #57 holding.
- Prelude Capital Management first reported a position in Teva Pharmaceuticals in Q2 2014 and has held it in 26 quarters since.
- 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.
Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.